<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/326EF7F4-5944-472D-BC94-2CA4484AEE74"><gtr:id>326EF7F4-5944-472D-BC94-2CA4484AEE74</gtr:id><gtr:name>University of Groningen</gtr:name><gtr:address><gtr:line1>Postbus 72</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE713D42-FE8A-4117-AB3C-224D5A93265A"><gtr:id>CE713D42-FE8A-4117-AB3C-224D5A93265A</gtr:id><gtr:name>Heinrich Heine University D?sseldorf</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/326EF7F4-5944-472D-BC94-2CA4484AEE74"><gtr:id>326EF7F4-5944-472D-BC94-2CA4484AEE74</gtr:id><gtr:name>University of Groningen</gtr:name><gtr:address><gtr:line1>Postbus 72</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE713D42-FE8A-4117-AB3C-224D5A93265A"><gtr:id>CE713D42-FE8A-4117-AB3C-224D5A93265A</gtr:id><gtr:name>Heinrich Heine University D?sseldorf</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2F451708-3610-4099-9B27-1D90AF17C23A"><gtr:id>2F451708-3610-4099-9B27-1D90AF17C23A</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Gordon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1BAE1842-93F0-4C9E-850D-7BD60FDF8914"><gtr:id>1BAE1842-93F0-4C9E-850D-7BD60FDF8914</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Balfe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0"><gtr:id>92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>Alison</gtr:otherNames><gtr:surname>McKeating</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400802"><gtr:id>54E4F8D4-62D5-419C-93D8-A923CDC06505</gtr:id><gtr:title>The role of neutralising antibodies in hepatitis C virus infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400802</gtr:grantReference><gtr:abstractText>Hepatitis C virus (HCV) is the major etiological agent of liver disease in most regions of the world. The majority of new infections become chronic and these individuals are at high risk for developing progressive liver disease. However, a minority of individuals (20%) resolve their infection and clear HCV to undetectable levels. We are interested in studying the immune parameters that distinguish these individuals from those where the virus persists. We will study the role of antibodies that have the potential to bind virus and prevent infection of new cells within the liver. Research findings from this proposal with immediate clinical relevance will be translated to the general public by interviews with the local press and through the MRC web site.</gtr:abstractText><gtr:technicalSummary>Hepatitis C virus (HCV) is the major etiological agent of liver disease in most regions of the world, with approximately 170 million individuals infected. Chronic HCV infection is also associated with disturbances in B lymphocyte function, including mixed cryoglobulinemia and B-cell lymphoma. Cellular and humoral immune responses are generated during HCV infection, however they are insufficient to effect viral clearance in the majority of individuals, with approximately 80% of new infections becoming chronic. However, the 20% of patients who resolve their infection provide an invaluable resource for studying the immune correlates of virus clearance. Recent studies of acute resolving infection provide compelling evidence that protective immunity exists: however, the immune factors that determine resolution versus chronic infection are poorly defined. The presence of an early and strong intrahepatic CD4+/CD8+ T-cell response appears to associate with early control of acute HCV infection. However, the role of nAbs in HCV infection and disease progression is unclear, largely due to the lack of assays that measure and quantify their activity. The recent discovery that retroviral pseudotypes bearing HCV envelope glycoproteins are infectious for cultured liver cell lines makes it possible to study the role of nAbs in HCV infection. Our current research shows that the majority of individuals who resolve acute HCV infection demonstrate a cross-reactive nAb response within the first year of infection, whereas, chronically infected patients develop nAb responses much later. We hypothesize that development of an early cross-reactive nAb response contributes to the immune control and clearance of HCV. To test this, we will study the evolution and specificity of the HCV specific nAb response in acute infection, comparing individuals who resolve HCV to those who progress to chronic infection. We will also study autologous nAb responses and determine if HCV evolves escape variants, with the goal of identifying the key differences in the early nAb response in patients who resolve acute HCV compared to those with persistent infection. These data will be critical both for the interpretation of current HCV env gp vaccine trials and for the future design of prophylactic and therapeutic vaccine immunogens. Finally, we will develop model systems to study HCV-B cell interaction(s) to address the mechanism(s) underlying the delayed appearance of nAbs in persistently infected patients and to elucidate the general B-cell abnormalities observed in chronically infected patients.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>650000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Ellie Barnes - To study the role of neutralizing antibodies in hepatitis C virus infection.</gtr:description><gtr:id>50BC6F62-A927-4544-B6B7-4953C02D384C</gtr:id><gtr:impact>Stratified Medicine to Optimise the Treatment of Patients with Hepatitis C Virus Infection (STOP-HCV). Investigators: Consortium of UK investigators, led by Ellie Barnes (Oxford University). Awarding body: MRC. Funds: &amp;pound;6.3M. Dates: 01/5/13 - 31/4/18.</gtr:impact><gtr:outcomeId>cb2PJoZBT1N-1</gtr:outcomeId><gtr:partnerContribution>Immunology expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Stan van der Graaf - To study the role of NTCP bile salt transporter in hepatitis B virus entry</gtr:description><gtr:id>39BFB17E-D336-4913-B660-C35362D10887</gtr:id><gtr:impact>Meredith, L.M., Hu, K., Cheng, X., Howard, C.R., Baumert, T.F., Balfe, P., van de Graaf, S.F., Protzer, U., and McKeating, J.A. Lentiviral hepatitis B pseudotypes uncover a role for NTCP and additional hepatocyte specific factors in virus entry. J Gen Virol. 97: 121-7, 2016.
Plus other manuscripts in preparation.</gtr:impact><gtr:outcomeId>DYx7rBZB17K-1</gtr:outcomeId><gtr:partnerContribution>Provision of stable cell lines expressing wild type and mutant NTCP.</gtr:partnerContribution><gtr:piContribution>Development of lentiviral pseudotypes expressing hepatitis B virus (HBV) glycoproteins and to study the role of NTCP in mediating viral infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heinrich Heine University D?sseldorf</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute of Virology</gtr:department><gtr:description>Ulla Protzer - To study the mechanism of hepatitis B virus entry</gtr:description><gtr:id>F6EB70E6-4FEF-48FB-A959-F3F29BAA991C</gtr:id><gtr:impact>WT ISSF application to fund a training visit for Dr Luke Meredith to visit Protzer lab. Currently preparing a manuscript and MRC project grant with Protzer as a named collaborator.</gtr:impact><gtr:outcomeId>mGiNJDugU9J-1</gtr:outcomeId><gtr:partnerContribution>Provision of hepatitis B virus molecular clones and to advise on differentiation protocols for the bipotent HepaRG cell line.</gtr:partnerContribution><gtr:piContribution>Development of lentiviral pseudotypes expressing hepatitis B virus glycoproteins and to characterise their infectivity for a range of cell types</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Thomas Baumert - To study the mechanism of hepatitis C virus entry into polarized hepatocytes.</gtr:description><gtr:id>4F3C9492-CBC6-4166-99DF-18A811C86B64</gtr:id><gtr:impact>Zona, L., Lupberger, J., Thumann, C., Ahmed-Adrar, N.S., Thumann, C., Harris, H.J., Barnes, A., Florentin, J., Taware, R.G., Xiao, F., Turek, M., Durand, S.C., Duong, F.H., Heim, M.H., Cosset, F-L., Hirsch, I., Brino, L., Zeisel, M.B., Le Naour, F., McKeating, J.A. and Baumert, T.F. (2013). HRas signal transduction mediates hepatitis C virus entry by triggering the assembly of the host tetraspanin receptor complex. Host Cell and Microb 13: 302-13.
Fofana, I., Zona, L., Thumann, C., Heydmann, L., Durand, S.C., Lupberger, J., Blum, H.E., Pessaux, P, Gondeau, C., Reynolds, G.M., McKeating, J.A., Grunert, F., Thompson, J., Zeisel, M.B., and Baumert, T.F. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes using monoclonal antibodies. J Virol, in press.
Farquhar, M. J., Hu, K., Harris, H.J., Davis, C., Brimacombe, C.L., Baumert, T.F., Rappoport, J.Z., Balfe, P., and McKeating, J.A. (2012). Hepatitis C virus promotes CD81 and claudin-1 endocytosis. J Virology 86: 4305-16.
Fletcher, N.F., Wilson, G.K., Murray, J., Hu, K., Lewis, A., Reynolds, G., Stamataki, Z., Meredith, L.W., Rowe, I.A., Luo, G., Lopez-Ramirez, M.A., Baumert, T. F., Weksler, B., Couraud, P.O., Kim, S.K., Romero, I.A., Jopling, C., Morgello, S., Balfe, P., and McKeating, J.A. (2012). Hepatitis C virus infection of blood brain barrier endothelial cells. Gastroenterology 142: 634-643.
Lupberger, J., Zeisel, M.B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., Mee, C.J., Turek, M., Gorke, S., Royer, C., Fischer, B., Zahid, M.N., Lavillette, D., Fresquet, J., Cosset, F-L., Rothenberg, S.M., Pietschmann, T., Patel, A.H., Pessaux, P., Doffeol, M., Raffelsberger, W., Poch, O., McKeating, J.A., Brino, L., and Baumert, T.F. (2011). EGF receptor and EphA2 are hepatitis C virus host entry factors and targets for antiviral therapy. Nat Med, 17: 589-95.
Syder, A.J, Lee, H., Zeisel, M.B., Grove, J., Soulier, E., Macdonald, J., Chow, S., Chang, J., Baumert, T.F., McKeating, J.A., McKelvy, J., Wong-Staal, F. (2011). Small molecule scavenger receptor B1 antagonists are potent HCV entry Inhibitors. J. Hepatology, 54, 48-55.
Brimacombe, C., Grove, J., Meredith, L., Hu, K., Syder, A.J., Flores, M.F., Timpe, J., Krieger, S.E., Baumert, T.F., Tellinghuisen, T.L., Wong-Staal, F., Balfe, P., and McKeating, J.A. (2011). Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission. J.Virology, 85, 596-605. 
Fletcher, N.F., Yang, J.P., Farquahr, M.F., Hu, K., Davis, C., He, Q., Dowd, K., Ray, S.C., Krieger, S.E., Baumert, T.F., Balfe, P., Wong-Staal, F., and McKeating, J.A. (2010). Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology, 139: 1365-1374.
Fofana, I., Krieger, S.E., Grunert, F., Glauben, S., Xiao, F., Fafi-Kremer, S., Soulier, E., Royer, C., Mee, C.J., McKeating J.A., Dragic, T., Schuster, C., Thompson, J., and Baumert, T.F. (2010). Monoclonal anti-Claudin 1 antibodies for the prevention of hepatitis C virus infection. Gastroenterology, 139:953-64.
Krieger, S.E., Zeisel, M.B, Davis, C., Thumann, C., Harris, H.J., Schnober, E.K., Mee, C.J., Soulier, E., Lambotin, M., Grunert, F., Loan Dao Thi, V., Dreux, M., Cosset, F-L., McKeating, J.A., Schuster, C., and Baumert, T.F (2010). Inhibition of hepatitis C virus infection by anti Claudin antibodies is mediated by neutralization of E2-CD81-Claudin 1 association(s). Hepatology, 51:1144-57.
Kapadia, S. B., Barth, H., Baumert, T., McKeating, J. A. &amp;amp; Chisari, F. V. (2007). Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virology 81, 374-383.</gtr:impact><gtr:outcomeId>egXQirWTpMc-1</gtr:outcomeId><gtr:partnerContribution>Complementary viral expertise.</gtr:partnerContribution><gtr:piContribution>Provide imaging expertise of viral receptor trafficking.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adam Cunningham - Viral-bacterial coinfection</gtr:description><gtr:id>B03F67F3-85AD-45EE-B8A6-761B669C791B</gtr:id><gtr:impact>Grant :
Establishing model systems to study viral-bacterial co-infection. Investigators: Adam Cunningham and Jane McKeating. Awarding Body: MRC Centre for Immune Regulation, UoB. Funds: &amp;pound;85,000.Dates: 01/10/12 -31/9/16.</gtr:impact><gtr:outcomeId>dTFViqSjKcz-1</gtr:outcomeId><gtr:partnerContribution>anti-bacterial immunology</gtr:partnerContribution><gtr:piContribution>virology expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Freek van Eeden - In vitro validation of HIF-GR cross-talk.</gtr:description><gtr:id>E218393D-D82C-42E9-8766-F32136568EB9</gtr:id><gtr:impact>A manuscript is currently under review.</gtr:impact><gtr:outcomeId>NgtjRt4Wh74-1</gtr:outcomeId><gtr:partnerContribution>Provision of VHL null zebrafish model.</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise and clinical material to study HIF-1a/GR cross-talk and functional consequences for viral persistence
.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Munich</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>HEPacute</gtr:description><gtr:id>4CAA87B1-4802-4BCB-ACD8-3C2DD89B3A53</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>pQnjFEX6hJH-1</gtr:outcomeId><gtr:partnerContribution>Access to European HCV samples</gtr:partnerContribution><gtr:piContribution>FP7 network to investigate corrrelates of viral clearance in acute infection</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Groningen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Sven IJzendoorn - To study the role of hepatocyte polarity in hepatitis C virus infection.</gtr:description><gtr:id>0F633C4E-C6AB-4795-B25D-A76363523306</gtr:id><gtr:impact>Harris, H.J., Clerte, C., Fraquhar, M,J., Goodall, M., Hu, K., Rassam, P., Dosset, P., Wilson, G.K., Balfe, P., IJzendoorn, S.C., Milhiet, P.E. and McKeating, J.A. (2013). Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Cellular Micro 15: 430-45. 

Mee, C. J., Harris, H. J., Farquhar, M. J., Wilson, G., Reynolds, G., Davis, C., van, IJzendoorn, S. C., Balfe, P. &amp;amp; McKeating, J. A. (2009). Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virology 83, 6211-6221. 

Farquhar, M. J., Harris, H. J., Diskar, M., Jones, S., Mee, C. J., Nielsen, S. U., Brimacombe, C. L., Molina, S., Toms, G. L., Maurel, P., Howl, J., Herberg, F. W., van Ijzendoorn, S. C., Balfe, P. &amp;amp; McKeating, J. A. (2008). Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virology 82, 8797-8811.</gtr:impact><gtr:outcomeId>bbsF4mb9JoH-1</gtr:outcomeId><gtr:partnerContribution>Hepatocyte polarity expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>EC FP6 Collaborative Projects</gtr:department><gtr:description>Hepacivac (FP6 programme)</gtr:description><gtr:id>0038F15B-965B-47D1-AEBA-60D24BD52A09</gtr:id><gtr:impact>Relevant publications include 17941058, 18838615, 18829747, 19052239 and 19321602.</gtr:impact><gtr:outcomeId>B3E87DD20A9-1</gtr:outcomeId><gtr:partnerContribution>This network provides us with expertise in vaccine preparation, cell mediated immunity and animal models, all of which have strengthened our work.</gtr:partnerContribution><gtr:piContribution>Test in vitro neutralising antibody responses in pre-clinical evaluations of candidate HCV vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Thomas Krey - To study the mechanism of hepatitis C virus neutralization.</gtr:description><gtr:id>4F01FE99-2AF6-493E-ABDB-AAC79DA9B103</gtr:id><gtr:impact>'Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.' &amp;nbsp;Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T,&amp;nbsp;J Virol, 89: 2170-81, 2015.

'An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.' &amp;nbsp;Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T,&amp;nbsp;Hepatology, 58: 932-9, 2013.</gtr:impact><gtr:outcomeId>YwJVq8CXg2v-1</gtr:outcomeId><gtr:partnerContribution>Structural biologist</gtr:partnerContribution><gtr:piContribution>Viral hepatitis Expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dan Tennant - To study the role of hypoxia on hepatitis C and B replication.</gtr:description><gtr:id>8B5FEE27-9FFB-4819-B5B6-3BB9A4D9AEF7</gtr:id><gtr:impact>Wilson, G., Tennant, D and McKeating J.A (2013). Hypoxia, viruses and liver injury. J Hepatology, invited review. 

A manuscript is currently under preparation and planning to submit MRC Project grant next year.</gtr:impact><gtr:outcomeId>iz7gNG6px9t-1</gtr:outcomeId><gtr:partnerContribution>Provision of hypoxia expertise.</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise and clinical material.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Tao Dong - To study the immunology of HIV-HCV coinfection</gtr:description><gtr:id>4020AEC9-7228-4188-AC48-35751EF6A66B</gtr:id><gtr:impact>Pathogen Co-infection &amp;quot;PathCo&amp;quot;: HIV, Tuberculosis, Malaria and hepatitis C virus Investigators: McKeating as a consortium member. Awarding Body: FP7. Funds: &amp;pound;280,000. Dates: 01/11/13 - 31/10/2017.</gtr:impact><gtr:outcomeId>CgpefGRa9oh-1</gtr:outcomeId><gtr:partnerContribution>HIV T cell immunity</gtr:partnerContribution><gtr:piContribution>viral hepatitis expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Immune Regulation</gtr:department><gtr:description>MRC centre for Immune Regulation</gtr:description><gtr:id>3F089CBE-D69A-4B72-B77A-3FDD75C30DCE</gtr:id><gtr:impact>Many of the publications we generated between 2006 and 2012 used the MRC centre facilities.</gtr:impact><gtr:outcomeId>pJHufLu7DJ7-1</gtr:outcomeId><gtr:partnerContribution>Provision of key core technologies and expertise</gtr:partnerContribution><gtr:piContribution>Access to shared facilities and provision of expertise</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heidelberg University</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Stephan Urban - the role of NTCP bile salt transporter in hepatitis B virus entry</gtr:description><gtr:id>4C696964-69AB-44DB-937D-8CF607583E87</gtr:id><gtr:impact>Baumert, T.F., Meredith, L., Yi, N., Felmlee, D.J., McKeating, J.A. and Urban, S. 2013. Entry of hepatitis B and C viruses - recent progress and future impact. Current Opinions in Virology, 2014.</gtr:impact><gtr:outcomeId>NQ1rnDHfSoh-1</gtr:outcomeId><gtr:partnerContribution>Provision of hepatitis B virus molecular clones and Myrcludex.</gtr:partnerContribution><gtr:piContribution>Development of lentiviral pseudotypes expressing hepatitis B virus (HBV) glycoproteins and to study the effect of a synthetic peptide that mimics viral encoded Pre-S1 glycoprotein (Myrcludex), currently under clinical evaluation, for it's effect on HBV entry.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Jeremy Tomlinson - To study the effect of HCV on insulin signaling.</gtr:description><gtr:id>ECF0875F-C07F-4A8B-812C-8E0A43AB0CA9</gtr:id><gtr:impact>Co-sponsors of Clinical Training Fellowship to Reina Lim. Hepatic steatosis and insulin resistance in hepatitis C infection. Awarding body: MRC. Funds: &amp;pound;356,000. Dates: 01/10/12 - 31/9/15. 

Linking Glucocorticoid Receptor Activation and Lipid Metabolism in the Pathogenesis of Hepatocellular Carcinoma. Investigators: Jeremy Tomlinson and Jane McKeating. Awarding Body: CMDS University of Birmingham. Funds: &amp;pound;85,000. Dates: 01/10/14 -31/9/17.
A paper is currently in preparation.</gtr:impact><gtr:outcomeId>TEswvSzj8Us-1</gtr:outcomeId><gtr:partnerContribution>Provide endocrinology expertise</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Antonio Bertoletti - To study the role of immune cells in hepatitis C entry and infection</gtr:description><gtr:id>A8574975-62D8-45F9-A145-2BAF4E1AC68E</gtr:id><gtr:impact>Fletcher, N.F., Sutaria, R., Juandy, J., Barnes, A., Blahova, M., Hu, K., Cosset, F-L., Balfe, P., Adams, D.H., Curbishley, S,M., Bertoletti, A. and McKeating, J.A. Activated macrophages promote hepatitis C virus entry in a tutor necrosis factor-dependent manner. Hepatology. 59: 1320-30, 2014.</gtr:impact><gtr:outcomeId>N8vrpG3Av7R-1</gtr:outcomeId><gtr:partnerContribution>Provide immunological expertise and access to liver perfusate.</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Margaret Ashcroft - To study the role of hypoxia on hepatitis C and B replication.</gtr:description><gtr:id>5AF7502A-31FA-4258-973D-8262D55AD95C</gtr:id><gtr:impact>Wilson, G., Brimacombe, C.L., Rowe, I.A., Reynolds, G.M., Fletcher, N.F., Stamataki, Z., Bhogal, R., Simoes, M., Ashcroft, M., Afford, S.C., Mitry, R., Dhawan, A., Mee, C.J., Hubscher, S.G., Balfe, P., and McKeating, J.A. (2012). A dual role for hypoxia factor 1-a in the hepatitis C virus lifecycle and hepatoma migration. J. Hepatology 56: 803-9.</gtr:impact><gtr:outcomeId>QSDbYFTifsM-1</gtr:outcomeId><gtr:partnerContribution>Provision of HIF-1a expression vectors and inhibitors.</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise and clinical material.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>David Adams - To study hepatitis C virus pathogenesis</gtr:description><gtr:id>416B5499-A46D-4E49-930F-9C424A6AD1E9</gtr:id><gtr:impact>Stamataki, Z., Tilakaratne, S., Adams, D.H., and McKeating, J.A. (2011). Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One 6(9):e25789.

Rowe, I.A., Wilson, G.K., Galsinh, S.K., Durrant, S., Lazar, C., Branza-Nichita, N., Bicknell, R., Adams, D.H., Balfe,P., and McKeating, J.A. (2013). Paracrine signals from liver sinusoidal endothelium regulate HCV replication. Hepatology, in press.

Fletcher, N.F., Sutaria, R., Juandy, J., Barnes, A., Blahova, M., Hu, K., Cosset, F-L., Balfe, P., Adams, D.H., Curbishley, S,M., Bertoletti, A. and McKeating, J.A. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology, in press.

Stamataki, Z., Shannon-Lowe, C., Shaw, J., Mutimer, D., Rickinson, A. B., Gordon, J., Adams, D. H., Balfe, P. &amp;amp; McKeating, J. A. (2009). Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 113, 585-593.

Reynolds, G. M., Harris, H. J., Jennings, A., Hu, K., Grove, J., Lalor, P. F., Adams, D. H., Balfe, P., Hubscher, S. G. &amp;amp; McKeating, J. A. (2008). Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47, 418-427.

Lai, W. K., Curbishley, S. M., Goddard, S., Alabraba, E., Shaw, J., Youster, J., McKeating, J. A &amp;amp; Adams, D. H. (2007). Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J Hepatology 47, 338-347.

Grants: 
Liver Biomedical Research Unit to study Immune and cell therapy of liver disease. Investigators: Adams, McKeating, Newsome, Stewart, Johnson, Young. Awarding Body: National Institute of Health Research (UK). Funds: &amp;pound;6.35 million. Dates: 2012-2017.</gtr:impact><gtr:outcomeId>kvDZ4YBt82L-1</gtr:outcomeId><gtr:partnerContribution>Immunological expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis Expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Alex Tarr - To study the role of neutralising antibodies in hepatitis C virus infection.</gtr:description><gtr:id>E2FE49C5-7B9B-4842-A425-BAE88491AF91</gtr:id><gtr:impact>Tarr, A.W., Lafayem P., Meredith, L., Damier-Piolle, L., Urbanowicz, R.A., Meola, A., Jestin, J-L., Brown, R.J.P., McKeating, J.A., Rey, F.A., Ball, J.K. and Krey,T. (2013). A recombinant nano body inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology. 58: 932-9.

Brown, R.J.P., Hudson, N., Wilson, G., Rehman, S.U., Jabbari, S., Tarr, A.W., Borrow, P., Joyce, M. Lewis, J., Zhu L.F., Law, M., Kneteman, N., Tyrell, D.L., McKeating, J.A. and Ball, J. (2012). Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J.Virol 86: 119566 - 66. 

Tarr, A.W., Urbanowicz, R.A., Jayaraj, D., Brown, R.J.P., McKeating, J.A., Irving, W.L., and Ball, J.K. (2012). Naturally occurring antibodies recognizing linear epitopes in the amino-terminus of the hepatitis C virus E2 protein confer non-interfering, additive neutralization. J.Virol 86: 2739-49.

Law, M., Maruyama, T., Lewis, J., Giang, E., Tarr, A. W., Stamataki, Z., Gastaminza, P., Chisari, F. V., Jones, I. M., Fox, R. I., Ball, J. K., McKeating, J. A., Kneteman, N. M. &amp;amp; Burton, D. R. (2008). Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14, 25-27.

Submitted MRC project application in 2013 that was unsuccessful despite excellent scores - plan to re-submit.</gtr:impact><gtr:outcomeId>cRt2SLmvn3m-1</gtr:outcomeId><gtr:partnerContribution>Immunology expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Research Seminar, Institute Pasteur</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FBFC1DE0-3A28-412A-8593-A35F82F78E41</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>58c6484a3242c3.99171297</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Big Bang Fair</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0C7DB960-AC0D-4BEA-8E1C-97C639C57983</gtr:id><gtr:impact>Ran activity at the &amp;quot;Big Bang Fair&amp;quot; - a national science fair at the Birmingham NEC targeted to School years 7 - 11 with &amp;gt; 15,000 attendees.
Also acted as Judge for national science scheme entries.</gtr:impact><gtr:outcomeId>56dc649c6281b3.75655789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Darwin day lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6BD8EE9E-4B83-496A-9E02-3A894F613C89</gtr:id><gtr:impact>Gave keynote presentation on processes of viral evolution, with a focus on HCV

Invited to present again. Positive feedback from audience evaluation forms.</gtr:impact><gtr:outcomeId>B90EEA6D4E5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, Freiburg</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1ABCD831-1138-4F5F-B080-2B48796F35F8</gtr:id><gtr:impact>Research seminar and collaborative meeting</gtr:impact><gtr:outcomeId>58c646d6120027.84249718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School prize giving &amp; lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4AD00DD8-1363-4D5E-8324-053AECA32E6E</gtr:id><gtr:impact>Gave talk on women in science, careers and research. Presented School prizes

School reported strengthening of science curriculum</gtr:impact><gtr:outcomeId>79A558E6AB0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, King's College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2F07305C-5003-45F3-99D3-3718ADBE820A</gtr:id><gtr:impact>Invited research Seminar</gtr:impact><gtr:outcomeId>58c648c2ba9495.83334161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HepCar Kick off meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>17AE6512-6B92-4822-A54E-6F5FC955A607</gtr:id><gtr:impact>Address to Meeting, chair of Research committee</gtr:impact><gtr:outcomeId>58c646797a3507.36822757</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEMnet ambassador scheme</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9D4DAA5F-F4E4-4DC8-B1D4-5FBF72ADFCB5</gtr:id><gtr:impact>&amp;gt;20 ambassadors from MDS are now actvively engaged in visits to West Midlands Schools and MDS has become the largest group at UoB to send people out on these visits. In the last year 45 visits were made and we estimate &amp;gt;1,000 children (and their teachers) were visited.

Several of our ambassadors are visiting schools for the third year running and the schools appreciate the presence of UoB in their community</gtr:impact><gtr:outcomeId>s5J9nVTQroN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8B6C53E0-5757-4C2B-9507-4A040D251252</gtr:id><gtr:impact>Plenary speaker at Conference</gtr:impact><gtr:outcomeId>58c645fbc43461.22957529</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits and lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0E974146-3C4B-4464-9327-E6E9A7A347C3</gtr:id><gtr:impact>Virology talks to 6th form students, with description of research career and role of women in science.

Teachers reported that several students chose to study Biology or Medicine as a result of these talks (indeed one of these students is now on our course in Birmingham).</gtr:impact><gtr:outcomeId>E3C3AD3768C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PathCo Meeting, Sienna</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D061CF41-6C0D-463D-A61E-DBC0A773826D</gtr:id><gtr:impact>Chair of Scientific session and presenter</gtr:impact><gtr:outcomeId>58c64731269821.92761286</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, WIMM, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B558C498-9842-47CB-A232-0C27509EB8D2</gtr:id><gtr:impact>Research Seminar</gtr:impact><gtr:outcomeId>58c6488548d115.25385341</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Careers fairs</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>80A5AD0C-39AF-445D-BF78-9E832DF3C13C</gtr:id><gtr:impact>Had several students apply to UoB on the basis of our presentations. To date these careers talks have been give to over 500 17-18 year olds

Repeat visits invitations from all schools involved. several work experience students have applied for time in our department on the basis of these activities.</gtr:impact><gtr:outcomeId>mMbrF7GoAtN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of Science lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6D3BEA2A-F97F-4596-BC19-C1DF1EB4A744</gtr:id><gtr:impact>Pint of Science is an international initiative to enhance public understanding of science. We took part in the inaugural series in Birmingham in 2015.</gtr:impact><gtr:outcomeId>56dc63d8ed3de5.43517943</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, IAS, TUM, Munich</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C37ED0EB-CD17-4D9A-9F16-6AF725313C15</gtr:id><gtr:impact>Research seminar</gtr:impact><gtr:outcomeId>58c6479a463c71.41528492</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Flak International Meeting, basic science to clinical practice</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3654A0AA-40BA-4401-B386-27E5E78DCD5E</gtr:id><gtr:impact>Plenary session at policy forum</gtr:impact><gtr:outcomeId>58c647faaee9a7.18377029</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School science weeks</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2989DFCB-D2F5-4FE2-9B5C-1325669E018D</gtr:id><gtr:impact>Series of hands on experience of microbiology for primary school children.

School reports improved KS2 results and better understanding of health among children</gtr:impact><gtr:outcomeId>10DD0C07164</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2022-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8D7356E8-AB5F-4F50-9616-C14CE75E0844</gtr:id><gtr:outcomeId>58c64a2bc1e025.72988672</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>69633</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BCH Research Studentship</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>BCH Charities</gtr:fundingOrg><gtr:fundingRef>BCHRF253</gtr:fundingRef><gtr:id>C4C1708D-4840-43CB-835C-877C9741C367</gtr:id><gtr:outcomeId>FfUeJwDs4yv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>363000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>68C67DC6-6E60-48DF-8EA9-3E203D598038</gtr:id><gtr:outcomeId>CA5DB89D8940</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Birmingham Liver Biomedical Research Unit</gtr:department><gtr:description>Biomedical Research Unit</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F9846441-4C98-46F5-9F85-942D8F8AFE69</gtr:id><gtr:outcomeId>573FEA6BDB50</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>329505</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Research Grant (FP7, Hepacute)</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>950BD269-F6C3-421B-A371-342699B3F928</gtr:id><gtr:outcomeId>QR2vp6W43sM</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Merit Award</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>D608CFE1-026E-4E9C-B744-6D6CDBF8A9D8</gtr:id><gtr:outcomeId>FCA3C6224AE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1253354</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Research Grant (FP7 PathCo)</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4856F501-1F92-4333-A581-BDD1DAA1C362</gtr:id><gtr:outcomeId>MRwaN7aACsr</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>154840</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Fellowship (Recoin)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>3B467E70-8A54-45BF-B4E8-22D53AE51532</gtr:id><gtr:outcomeId>FEjDNyZKyyn</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>767361</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme grant (Model systems to study hepatitis C virus tropism for the liver)</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A56E6CC1-C7FF-465D-9F12-2A03F718724C</gtr:id><gtr:outcomeId>676BD69BABF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>201043</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Studentship (WT)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>2F026A34-C0DE-4439-A175-97C26CFF64EC</gtr:id><gtr:outcomeId>arbt3HcCDme</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clarendon Scholarship</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>368431BA-775A-4D60-9575-DE7A28828F46</gtr:id><gtr:outcomeId>58c64a8fed6787.24082603</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>189694</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant (ROTRF)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Roche Organ Transplantation Research Foundation (ROTRF)</gtr:fundingOrg><gtr:id>1B07C9F3-B6C5-4CD8-84AE-B0E6786248AC</gtr:id><gtr:outcomeId>HVuML4fP9Kr</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>172000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (FP6, Hepacivac)</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>59F73920-A61B-44DC-AF7B-C051702257EC</gtr:id><gtr:outcomeId>72B649E93710</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>241000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (Pfizer)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>DDC22E5B-8902-49A7-A734-89859FED3E4A</gtr:id><gtr:outcomeId>1135416B3600</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>419000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C864537A-C0C1-43E1-AB0D-C90CD2D987BC</gtr:id><gtr:outcomeId>AEC83A405450</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1248546</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>978F51FF-4E24-4D66-9834-466E6F1B0A6A</gtr:id><gtr:outcomeId>jwdGuMHbQtf0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A culture system to evaluate HCV infection of polarized hepatoma cell lines</gtr:description><gtr:id>DBCB0E24-4E27-436C-8065-4CFD9C101D3D</gtr:id><gtr:impact>Several groups are now re-assessing their infection models to take into account the effects of cell polarization.</gtr:impact><gtr:outcomeId>23C9C2F8228</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Polarized HepG2 infection system</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An assay was developed to quantify the degree of direct cell to cell transfer of HCV in the presence of neutralising antibodies</gtr:description><gtr:id>6A0C5092-C719-4555-AA5B-CF6C58A80001</gtr:id><gtr:impact>These experiments have led to several groups re-assessing the likely efficacy of mAb based therapies</gtr:impact><gtr:outcomeId>CA84CC9CBBB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Assay for cell to cell transmission of HCV</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5918D553-919A-419B-BDCB-DEF7DAFC8364</gtr:id><gtr:title>Humoral immune response in acute hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/643b5530cef1fb371a0a27eee16515ec"><gtr:id>643b5530cef1fb371a0a27eee16515ec</gtr:id><gtr:otherNames>Netski DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>FB84C6C35FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8CE3438-989A-4624-A90A-FA501072BC6F</gtr:id><gtr:title>Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d20aac3bd0b3b0b09dda180803b31989"><gtr:id>d20aac3bd0b3b0b09dda180803b31989</gtr:id><gtr:otherNames>Timpe JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>589A565491A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7AE42C2-3342-4697-8AF0-77036C81AB46</gtr:id><gtr:title>Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ddc2fb2a78327bb10beb12110e4d7d"><gtr:id>77ddc2fb2a78327bb10beb12110e4d7d</gtr:id><gtr:otherNames>Kapadia SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>8C82842E0E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32ACD177-1137-49DB-B122-D08C8327EC13</gtr:id><gtr:title>Hepatitis C virus entry and the tetraspanin CD81.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15282_22_21428934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8C0A0E3-755C-4698-8218-97049077DB9F</gtr:id><gtr:title>Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ff4c4c49807475824c370c30580373b"><gtr:id>0ff4c4c49807475824c370c30580373b</gtr:id><gtr:otherNames>Tscherne DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>8127D34634E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5465BFA-5EB9-42D9-8DED-8BDDE3F19C61</gtr:id><gtr:title>A dual role for hypoxia inducible factor-1a in the hepatitis C virus lifecycle and hepatoma migration.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15282_22_22178269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C8E09EB-064D-4767-86D7-C35E8B95D0CC</gtr:id><gtr:title>Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>A74A84AAF65</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9027180-57DB-4905-8C90-2FA2807D6B88</gtr:id><gtr:title>Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6940caa80bc023cd10f951b128d76eb"><gtr:id>d6940caa80bc023cd10f951b128d76eb</gtr:id><gtr:otherNames>von Hahn T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>C9A615E6F0C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F3686BA-EA93-4FC2-98DB-78DD7E8A2147</gtr:id><gtr:title>Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/462130645d338d72568c32df2d9660bb"><gtr:id>462130645d338d72568c32df2d9660bb</gtr:id><gtr:otherNames>Evans MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>D147E5AD653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9077B9BD-DEB2-4A19-BB51-79B6E927E1DC</gtr:id><gtr:title>Hepatitis C virus entry and neutralization.</gtr:title><gtr:parentPublicationTitle>Clinics in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1089-3261</gtr:issn><gtr:outcomeId>18587536F1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF921478-5EB5-417C-BF7D-944D6A894676</gtr:id><gtr:title>Primary hepatocytes as targets for hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>ndERCX6tbyc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89C7D66B-4D48-4AB8-8A47-814825BE7061</gtr:id><gtr:title>Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90b707b0a82725422ada99831ecc90b7"><gtr:id>90b707b0a82725422ada99831ecc90b7</gtr:id><gtr:otherNames>Lake-Bakaar G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>D416F4435FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>518EBF9C-2F7A-4ECB-A6B8-F218BEF34388</gtr:id><gtr:title>Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22171278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E29AA2A4-4994-4E63-B101-0D0861A0A370</gtr:id><gtr:title>Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D3014BC1656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CABCE272-D47D-4BEF-BF32-877000B1EACB</gtr:id><gtr:title>Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4ab0f7d7971e405dfa06672fdb1cf3"><gtr:id>cb4ab0f7d7971e405dfa06672fdb1cf3</gtr:id><gtr:otherNames>Lindenbach BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>13F8690BE4F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53FA5811-EB95-4FB1-930A-5294AEA25B8F</gtr:id><gtr:title>Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>jhngn21PSD8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>615F0EAE-7F7D-41AC-B4C1-BDE1C3C238FF</gtr:id><gtr:title>Persistent hepatitis C virus infection in vitro: coevolution of virus and host.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6accc41aa5b93cbc68878475fac5b8cb"><gtr:id>6accc41aa5b93cbc68878475fac5b8cb</gtr:id><gtr:otherNames>Zhong J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>3DC28AD5A16</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F16D8C89-B014-4962-8842-D9081DBC856F</gtr:id><gtr:title>The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein</gtr:title><gtr:parentPublicationTitle>Journal of Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f1d6c7ceb05f9f1de93d7380efc1158"><gtr:id>9f1d6c7ceb05f9f1de93d7380efc1158</gtr:id><gtr:otherNames>Helle F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>4F104B7B9F5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CEB4EA3-CE06-4FF6-8D9C-FC6527AEF678</gtr:id><gtr:title>Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2b4f6fdb72f1cdaef37b28a889ce1e7"><gtr:id>d2b4f6fdb72f1cdaef37b28a889ce1e7</gtr:id><gtr:otherNames>Desombere I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56cddd20a29a86.18706153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27192DB5-A2B8-442F-B399-67377D772F58</gtr:id><gtr:title>Diverse CD81 proteins support hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/164a8ad5e23271c68a0bda86e09a7c04"><gtr:id>164a8ad5e23271c68a0bda86e09a7c04</gtr:id><gtr:otherNames>Flint M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>A6556BC6BF0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E78E32BA-8E4F-4C69-88BE-EA0AACA18572</gtr:id><gtr:title>Hepatitis C virus infection of neuroepithelioma cell lines.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>RCvdbqNugWZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BF85DF0-AA9C-459A-BE5A-0BE4BAF674BF</gtr:id><gtr:title>Structural characterization of CD81-Claudin-1 hepatitis C virus receptor complexes.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47a7e0c1a30cbdc3c9114d7bc4876109"><gtr:id>47a7e0c1a30cbdc3c9114d7bc4876109</gtr:id><gtr:otherNames>Bonander N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15282_22_21428935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97A43FB6-86F4-4115-917C-DB357C028F54</gtr:id><gtr:title>Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1e35a161241c08af0a83743707122f7"><gtr:id>e1e35a161241c08af0a83743707122f7</gtr:id><gtr:otherNames>Lai WK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>8B6600983E9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13258709-CBB7-4785-9841-5F75740D5598</gtr:id><gtr:title>Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e893673af806c3cb89c50d861de13e4"><gtr:id>2e893673af806c3cb89c50d861de13e4</gtr:id><gtr:otherNames>Kaplan DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>4695BAE6B56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F055B83E-FFF9-4A1C-8060-F6E07C8FC872</gtr:id><gtr:title>Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>1F2B5F21866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B450F74-DFB3-4112-A1D3-AC6565F95CE2</gtr:id><gtr:title>Structural characterization of recombinant human CD81 produced in Pichia pastoris.</gtr:title><gtr:parentPublicationTitle>Protein expression and purification</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b08d2b7f9fc00bcd87fca83ab5372507"><gtr:id>b08d2b7f9fc00bcd87fca83ab5372507</gtr:id><gtr:otherNames>Jamshad M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1046-5928</gtr:issn><gtr:outcomeId>6E833DA3A26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FE912CB-5DE0-412B-A6B6-2617AF74518E</gtr:id><gtr:title>Effect of cell polarization on hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D1BCEB202FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0E91A74-8F61-4909-81AF-839E5DE5402C</gtr:id><gtr:title>Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>986B024AA54</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED8274A2-C63E-435B-B883-0B7A245B7E96</gtr:id><gtr:title>Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffb3d69db62b4506befe77f9713c06f7"><gtr:id>ffb3d69db62b4506befe77f9713c06f7</gtr:id><gtr:otherNames>Mathiesen CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5675e4eb8b58c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64D323C0-5AE3-4762-95FB-58E58B48412A</gtr:id><gtr:title>CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c9d36662cb20471af6a26537b90de2"><gtr:id>72c9d36662cb20471af6a26537b90de2</gtr:id><gtr:otherNames>Harris HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>7B51DA9E955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>956AA6EB-4531-4098-A6B7-D0A819B38233</gtr:id><gtr:title>In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7db0f8aa3dff74a26cb87933de072153"><gtr:id>7db0f8aa3dff74a26cb87933de072153</gtr:id><gtr:otherNames>Davis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>pm_15282_22_22897233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4144E97B-2777-4970-8F2C-1BEF22ACB8D2</gtr:id><gtr:title>Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5181c7d6d325ef99611d4b8158fa5a75"><gtr:id>5181c7d6d325ef99611d4b8158fa5a75</gtr:id><gtr:otherNames>Schwarz AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>149E710A7C4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E68A2E0-8570-4FD8-91F5-378619F48D7C</gtr:id><gtr:title>Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55308829b0f2e78b8deb7e8dbd9a471c"><gtr:id>55308829b0f2e78b8deb7e8dbd9a471c</gtr:id><gtr:otherNames>Brimacombe CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>kizQrUy44Lu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CDBB746-AC77-4A0B-AD74-E19F3B1F4E83</gtr:id><gtr:title>Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6940caa80bc023cd10f951b128d76eb"><gtr:id>d6940caa80bc023cd10f951b128d76eb</gtr:id><gtr:otherNames>von Hahn T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>2A44B389445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B518776-8AD2-4008-A603-EA1175589421</gtr:id><gtr:title>High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc69287aca943f9da74db554607d91d4"><gtr:id>fc69287aca943f9da74db554607d91d4</gtr:id><gtr:otherNames>Hedegaard DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a35e34038a321.50887883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48C4F0F7-6764-4871-B80C-97F3F0750EB2</gtr:id><gtr:title>Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdfb66698bf12de7c9639a895d0cb7e8"><gtr:id>bdfb66698bf12de7c9639a895d0cb7e8</gtr:id><gtr:otherNames>Law M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>836CA2CC6EE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A67C8B2-C960-4FAB-8D1B-FAFD67D55FE3</gtr:id><gtr:title>Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>RoL1oQ4eQQK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A643E96E-B758-445A-AA66-6D21872B7419</gtr:id><gtr:title>In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aaf9275375c857c4f9d98d2eb2ea67b"><gtr:id>9aaf9275375c857c4f9d98d2eb2ea67b</gtr:id><gtr:otherNames>Gal-Tanamy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>3951BFD600D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADA8443C-FA00-45DC-8BD6-BC495C00DDFF</gtr:id><gtr:title>Hepatitis C virus entry: possible targets for therapy.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d20aac3bd0b3b0b09dda180803b31989"><gtr:id>d20aac3bd0b3b0b09dda180803b31989</gtr:id><gtr:otherNames>Timpe JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>4353E4ED931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA67C710-D4A3-410F-84E8-5ACE3569B49F</gtr:id><gtr:title>Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>56cddd210c5370.98820982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0DFC7C8-59C7-4D8B-BBE2-54A769FCF55B</gtr:id><gtr:title>Participation of rab5, an early endosome protein, in hepatitis C virus RNA replication machinery.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a103f8418eae5e651516738352c486eb"><gtr:id>a103f8418eae5e651516738352c486eb</gtr:id><gtr:otherNames>Stone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_12_17301141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F953808C-762C-4FD7-A17A-86C79B2E23BC</gtr:id><gtr:title>Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1e35a161241c08af0a83743707122f7"><gtr:id>e1e35a161241c08af0a83743707122f7</gtr:id><gtr:otherNames>Lai WK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>2ADC9904341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA20BB0A-6C3C-4130-920A-1959FA32E85E</gtr:id><gtr:title>Glucocorticoids promote Von Hippel Lindau degradation and Hif-1a stabilization.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/360bbf1bba69620adc324a2fd79bb87e"><gtr:id>360bbf1bba69620adc324a2fd79bb87e</gtr:id><gtr:otherNames>Vettori A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a35e3de6f42d2.00177482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D65B06A-827A-41FE-AC02-6C57EFABB531</gtr:id><gtr:title>Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_540e13ce13c1bc11e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>660DA431-3636-4747-9350-A775F21E4161</gtr:id><gtr:title>A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.</gtr:title><gtr:parentPublicationTitle>Wellcome open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2398-502X</gtr:issn><gtr:outcomeId>5a2fd686ab7d17.93512529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>470232F9-EEDE-40FA-804F-3F7E74627215</gtr:id><gtr:title>Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39fa156771b11e594ede29bd67666cdf"><gtr:id>39fa156771b11e594ede29bd67666cdf</gtr:id><gtr:otherNames>Mailly L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>56cddd213f3151.63104440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>364C2621-0868-4D55-AF71-2497C6EDEFFC</gtr:id><gtr:title>Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5bded635fcd0ab8d05007017a49ea62"><gtr:id>a5bded635fcd0ab8d05007017a49ea62</gtr:id><gtr:otherNames>Fofana I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>UQqf2HfGABa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>823E7D90-0AB4-452F-B8A7-50489DDF595E</gtr:id><gtr:title>In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6940caa80bc023cd10f951b128d76eb"><gtr:id>d6940caa80bc023cd10f951b128d76eb</gtr:id><gtr:otherNames>von Hahn T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>3D693B26A39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45F63BDD-9D56-4D31-932F-590826605FC5</gtr:id><gtr:title>Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/095dbbaf878d75dcdb302c7affaa8f40"><gtr:id>095dbbaf878d75dcdb302c7affaa8f40</gtr:id><gtr:otherNames>Syder AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>kJoHtys9txH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C71B7A04-E099-47C3-9C72-3D723829B2CD</gtr:id><gtr:title>Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>BQUVteRfakE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38F74E44-CB11-4C86-885E-63A29516BBF7</gtr:id><gtr:title>Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef440b91f08c078acac798192ced855f"><gtr:id>ef440b91f08c078acac798192ced855f</gtr:id><gtr:otherNames>Krieger SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>nqJX2h6eQ5V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4976F5EE-E619-4E11-8E4C-5A215380610C</gtr:id><gtr:title>Hepatitis C virus induces CD81 and claudin-1 endocytosis.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22318146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17FBE445-E509-4BB2-888A-BBD846236CFF</gtr:id><gtr:title>Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a60c7824f59e0c4cb6d4835142ea2c2"><gtr:id>9a60c7824f59e0c4cb6d4835142ea2c2</gtr:id><gtr:otherNames>Rouill? Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_12_16501092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA9F1FD1-0FED-4A83-BC94-1E004C1A8FF1</gtr:id><gtr:title>Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56cddd20d4a5d7.19537286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C74F7CE0-3267-485E-AB52-8EB157657DDB</gtr:id><gtr:title>Hepatitis C virus receptor expression in normal and diseased liver tissue.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c7bc4f2814d38789cf0c55fc1811ac9"><gtr:id>5c7bc4f2814d38789cf0c55fc1811ac9</gtr:id><gtr:otherNames>Reynolds GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>7E199E2FB1B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F85F3A46-3E07-4C3B-B15F-B7CA75A0C076</gtr:id><gtr:title>Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cfdb8ffc54679f2f25831b0dfd61977"><gtr:id>6cfdb8ffc54679f2f25831b0dfd61977</gtr:id><gtr:otherNames>Petrovic D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>Jgbz26TCaKv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ECA21C7-DD3B-4C49-9F5E-E048D8086E47</gtr:id><gtr:title>Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e5bc1756e96e835a0772ea0b6c44eaa"><gtr:id>3e5bc1756e96e835a0772ea0b6c44eaa</gtr:id><gtr:otherNames>Brown RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22855498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B555CBE5-65C7-400C-8431-F560B25FF8C8</gtr:id><gtr:title>Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a003248c37cce8d7df973b7017f3354f"><gtr:id>a003248c37cce8d7df973b7017f3354f</gtr:id><gtr:otherNames>Mizukoshi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>68B83A125E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51686A06-866F-4025-9426-D3B2AD026142</gtr:id><gtr:title>Complete replication of hepatitis C virus in cell culture.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4ab0f7d7971e405dfa06672fdb1cf3"><gtr:id>cb4ab0f7d7971e405dfa06672fdb1cf3</gtr:id><gtr:otherNames>Lindenbach BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>1476EA5B4BD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D871239-CDB2-4B5C-A95C-7A32B9A6270F</gtr:id><gtr:title>The complexities of hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fca135231efdea352f7b6008279f4f8"><gtr:id>2fca135231efdea352f7b6008279f4f8</gtr:id><gtr:otherNames>Balfe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>UqBbicTw5De</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C1D8D4C-D5CD-4E2B-A609-9D7EC416F629</gtr:id><gtr:title>TNF superfamily members promote hepatitis C virus entry via an NF-?B and myosin light chain kinase dependent pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>58b5554e6fcf35.78693952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE501003-4660-4BD8-84C4-C4CE13235150</gtr:id><gtr:title>Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58b555856aed16.73568455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>150E954A-2FF3-4D75-9DF6-6F250FDDE503</gtr:id><gtr:title>Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a784b2046abed7a3dc95b54864208b67"><gtr:id>a784b2046abed7a3dc95b54864208b67</gtr:id><gtr:otherNames>Molina S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>F682212F2A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>505F3F25-5268-4C9D-8BFA-0C2E0145BF38</gtr:id><gtr:title>Claudin association with CD81 defines hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c9d36662cb20471af6a26537b90de2"><gtr:id>72c9d36662cb20471af6a26537b90de2</gtr:id><gtr:otherNames>Harris HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>FvsU4mm8geR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CF73EF1-7C61-4322-9102-181CA061E270</gtr:id><gtr:title>Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>02D2C8A4D88</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38C5BD85-2958-4006-9E1F-C1D89CD38208</gtr:id><gtr:title>Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>6A1C527DA11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65163693-E003-47E6-848A-30E8539F4D02</gtr:id><gtr:title>Hepatitis C virus infection of cholangiocarcinoma cell lines.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5675dff8c1e5c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>315BAC78-6FC8-46C0-8F3A-CA59AED08759</gtr:id><gtr:title>Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae3b8b0391d7478fd888d57135e3f37e"><gtr:id>ae3b8b0391d7478fd888d57135e3f37e</gtr:id><gtr:otherNames>Keck ZY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>B10A9BA8D55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24B873ED-3B78-46B7-B607-0B2C4039463D</gtr:id><gtr:title>Multiple effects of silymarin on the hepatitis C virus lifecycle.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87ea4bcc15f1d3af2793c8d32d5aa836"><gtr:id>87ea4bcc15f1d3af2793c8d32d5aa836</gtr:id><gtr:otherNames>Wagoner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>nQCppDFNcLp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFFA256F-3ECE-4A4E-BDDB-9A32205C8612</gtr:id><gtr:title>Superinfection exclusion in cells infected with hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ff4c4c49807475824c370c30580373b"><gtr:id>0ff4c4c49807475824c370c30580373b</gtr:id><gtr:otherNames>Tscherne DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>E93A14F2876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D89B3889-6576-4DB4-916C-B9257E4ED0DC</gtr:id><gtr:title>Mechanisms of viral entry: sneaking in the front door.</gtr:title><gtr:parentPublicationTitle>Protoplasma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6aa76591c16a0efc9a1c55289404af6"><gtr:id>c6aa76591c16a0efc9a1c55289404af6</gtr:id><gtr:otherNames>Thorley JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-183X</gtr:issn><gtr:outcomeId>J9GbqLYxnMt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>663285F3-8D59-488F-801E-7BF7C84247C0</gtr:id><gtr:title>Development of novel therapies for hepatitis C.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ef2a2b91bf143dfecdce236f5e4de6e"><gtr:id>8ef2a2b91bf143dfecdce236f5e4de6e</gtr:id><gtr:otherNames>Lemon SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>DLGXpE6kCYh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04579608-EEA3-4A21-B9B8-74BE62E0DA4C</gtr:id><gtr:title>Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d84a8ec626304bd46399f5c70de06714"><gtr:id>d84a8ec626304bd46399f5c70de06714</gtr:id><gtr:otherNames>Tully DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>58b5554e40ef86.09171928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51EA6BFB-DBD8-4280-B0B0-811881637496</gtr:id><gtr:title>Hepatitis C virus infects the endothelial cells of the blood-brain barrier.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_15282_22_22138189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63CB1773-7F2C-4B85-B18F-96D2A992B1AE</gtr:id><gtr:title>EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c37da01b6bb7122f1c13b7a56c29b906"><gtr:id>c37da01b6bb7122f1c13b7a56c29b906</gtr:id><gtr:otherNames>Lupberger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>Tp7fnkBTGdb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA2EBDB4-53C2-44A6-A94D-72FD41DD46BF</gtr:id><gtr:title>Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5675df95d1db2</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400802</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>